drugset / Trial / NCT01697631

Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes

NCT01697631

Phase 4 Completed 131 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This this trial is conducted in Europe. The aim of this trial is to compare glycaemic control of biphasic insulin aspart 30 (BIAsp 30) alone or combined with insulin aspart(IAsp) in patients previously treated with conventional Biphasic Human Insulin 30/70.

Timeline

Start
2002-07-22
Primary completion
2003-04-24
Completion
2003-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic Subcutaneous
Background biphasic insulin aspart 30 Protein / enzyme biologic Subcutaneous